Clinical trial · Observational

Prognostic Value of CAR, AFR and Ferritin in Non-M3 AML

The Prognostic Significance of C-Reactive Protein to Albumin Ratio, Albumin to Fibrinogen Ratio, and Serum Ferritin Level in Newly Diagnosed De Novo Non-M3 Acute Myeloid Leukemia Patients

NCT07810829CI-TRIAL-00126180not yet recruitingClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

This prospective cohort study aims to evaluate the prognostic significance of the C-reactive protein-to-albumin ratio (CAR), albumin-to-fibrinogen ratio (AFR), and serum ferritin level in newly diagnosed de novo non-M3 acute myeloid leukemia patients at Assiut University Hospitals.

Conditions

Conditions (3)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Acute Myeloid Leukemia	Acute Myeloid Leukemia	CURATED_BROADER	0.80
De Novo Acute Myeloid Leukemia With Multilineage Dysplasia	Acute Myeloid Leukemia with Multilineage Dysplasia	ALIAS	0.90
Non-M3 Acute Myeloid Leukemia	—	UNRESOLVED	—

Interventions

Interventions (0)

Data not yet available

No intervention recorded.

Design

Arms and outcomes

Arms (1)

label
Single cohort: Newly diagnosed de novo non-M3 AML patients
description
Adult patients aged 18-65 years with newly diagnosed de novo non-M3 acute myeloid leukemia who will receive induction chemotherapy according to institutional protocols.

Primary outcomes (1)

measure
Overall survival
timeFrame
Up to 24 months
description
Time from the date of AML diagnosis to death from any cause or last follow-up for surviving patients.

Secondary outcomes (5)

measure
Complete remission rate after induction chemotherapy
timeFrame
Day 28 after induction chemotherapy
description
Proportion of patients achieving complete remission after induction chemotherapy, defined as bone marrow blasts less than 5%, absolute neutrophil count greater than 1.0 × 10⁹/L, platelet count greater than 100 × 10⁹/L, and independence from red cell transfusions.

Eligibility

Eligibility (as posted)

Sex: All
Minimum age: 18 Years
Maximum age: 65 Years

Show eligibility criteria text

Inclusion Criteria:

* Age 18 to 65 years

  * Newly diagnosed de novo non-M3 acute myeloid leukemia
  * Both sexes
  * Willingness to provide informed consent

Exclusion Criteria:

* \- Patient refusal
* Significant cardiac, hepatic, or renal disease
* Diabetes mellitus with polyneuropathy
* Severe organ dysfunction (modified Marshall score ≥ 2)
* History of MDS transformed to AML
* Previous blood transfusions
* Relapsed AML
* Previous exposure to chemotherapy or radiotherapy

References

Publications (4)

BACKGROUNDLiu X, Li Y, Zeng L, Li X, Chen N, Bai S, He H, Wang Q, Zhang C. A Review on Mechanochemistry: Approaching Advanced Energy Materials with Greener Force. Adv Mater. 2022 Nov;34(46):e2108327. doi: 10.1002/adma.202108327. Epub 2022 Mar 20. PMID 35015320
BACKGROUNDEtra JW, Canner JK, Aslam U, Nasr IW. Penetrating Trauma in Baltimore: An Analysis of the Effect of a Rise in Localized Violence by Age Group. J Surg Res. 2021 Jun;262:38-46. doi: 10.1016/j.jss.2020.11.083. Epub 2021 Feb 3. PMID 33545620
BACKGROUNDQuan DH, Counoupas C, Nagalingam G, Pinto R, Petrovsky N, Britton WJ, Triccas JA. Advax adjuvant formulations promote protective immunity against aerosol Mycobacterium tuberculosis in the absence of deleterious inflammation and reactogenicity. Vaccine. 2021 Apr 1;39(14):1990-1996. doi: 10.1016/j.vaccine.2021.02.041. Epub 2021 Mar 11. PMID 33714652
BACKGROUNDYoshie H, Sedukhina AS, Minagawa K, Oda K, Ohnuma S, Yanagisawa N, Maeda I, Takagi M, Kudo H, Nakazawa R, Sasaki H, Kumai T, Chikaraishi T, Sato K. A bioinformatics-to-clinic sequential approach to analysis of prostate cancer biomarkers using TCGA datasets and clinical samples: a new method for precision oncology? Oncotarget. 2017 Aug 24;8(59):99601-99611. doi: 10.18632/oncotarget.20448. eCollection 2017 Nov 21. PMID 29245927